Literature DB >> 27304222

Does Undersizing of Transcatheter Aortic Valve Bioprostheses during Valve-in-Valve Implantation Avoid Coronary Obstruction? An In Vitro Study.

Sina Stock1, Michael Scharfschwerdt1, Roza Meyer-Saraei2, Doreen Richardt1, Efstratios I Charitos3, Hans-Hinrich Sievers1, Thorsten Hanke1.   

Abstract

Background The transcatheter aortic valve-in-valve implantation (TAViVI) is an evolving treatment strategy for degenerated surgical aortic valve bioprostheses (SAVBs) in patients with high operative risk. Although hemodynamics is excellent, there is some concern regarding coronary obstruction, especially in SAVB with externally mounted leaflet tissue, such as the Trifecta (St. Jude Medical Inc., St. Paul, Minnesota, United States). We investigated coronary flow and hydrodynamics before and after TAViVI in a SAVB with externally mounted leaflet tissue (St. Jude Medical, Trifecta) with an undersized transcatheter aortic valve bioprosthesis (Edwards Sapien XT; Edwards Lifesciences LLC, Irvine, California, United States) in an in vitro study. Materials and Methods An aortic root model was constructed incorporating geometric dimensions known as risk factors for coronary obstruction. Investigating the validity of this model, we primarily performed recommended TAViVI with the Sapien XT (size 26 mm) in a Trifecta (size 25 mm) in a mock circulation. Thereafter, hydrodynamic performance and coronary flow (left/right coronary diastolic flow [lCF/rCF]) after TAViVI with an undersized Sapien XT (size 23 mm) in a Trifecta (size 25 mm) were investigated at two different coronary ostia heights (COHs, 8 and 10 mm). Results Validation of the model led to significant coronary obstruction (p < 0.001). Undersized TAViVI showed no significant reduction with respect to coronary flow (lCF: COH 8 mm, 0.90-0.87 mL/stroke; COH 10 mm, 0.89-0.82 mL/stroke and rCF: COH 8 mm, 0.64-0.60 mL/stroke; COH 10 mm, 0.62-0.58 mL/stroke). Mean transvalvular gradients (4-5 mm Hg, p < 0.001) increased significantly after TAViVI. Conclusions In our in vitro model, undersized TAViVI with the balloon-expandable Sapien XT into a modern generation SAVB (Trifecta) successfully avoided coronary flow obstruction. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 27304222     DOI: 10.1055/s-0036-1584356

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  3 in total

Review 1.  On the Mechanics of Transcatheter Aortic Valve Replacement.

Authors:  Lakshmi P Dasi; Hoda Hatoum; Arash Kheradvar; Ramin Zareian; S Hamed Alavi; Wei Sun; Caitlin Martin; Thuy Pham; Qian Wang; Prem A Midha; Vrishank Raghav; Ajit P Yoganathan
Journal:  Ann Biomed Eng       Date:  2016-11-21       Impact factor: 3.934

2.  Optimising the Haemodynamics of Aortic Valve-in-valve Procedures.

Authors:  Ren Jie Yao; Matheus Simonato; Danny Dvir
Journal:  Interv Cardiol       Date:  2017-05

3.  Distance between valvular leaflet and coronary ostium predicting risk of coronary obstruction during TAVR.

Authors:  Jun-Hyok Oh; Yuhei Kobayashi; Guson Kang; Takeshi Nishi; Martin J Willemink; William F Fearon; Michael Fischbein; Dominik Fleishmann; Alan C Yeung; Juyong Brian Kim
Journal:  Int J Cardiol Heart Vasc       Date:  2021-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.